Leading AI medical innovator Sean Khozin joins Owkin as an impact advisor

Duration:5 mins

Tags: Culture


Date:February 16th, 2023


Leading AI medical innovator Sean Khozin joins Owkin as an impact advisor

Sean Khozin MD, MPH, a physician-executive and data scientist with over a decade of experience in biomedicine and government, has joined Owkin as an Impact Advisor.

As an Impact Advisor, Dr Khozin will help turbocharge the AI biotech company’s efforts to discover and develop new drugs and diagnostics at scale. He will enhance Owkin’s work with United States-based medical centres, increase the impact of Owkin’s AI diagnostics in the US, and increase Owkin’s overall footprint in the US.

Dr Khozin was most recently CEO of CancerLinQ and Executive Vice President of American Society of Clinical Oncology. Prior to this, he was Global Head of Data Strategy and Data Science Innovation at Janssen R&D, Johnson & Johnson. He also led the FDA Oncology Center of Excellence’s bioinformatics, regulatory science, and clinical trial innovation efforts and was the founding Executive Director of Information Exchange and Data Transformation (INFORMED), the FDA’s first data science and technology incubator. Before working for the federal government, Dr Khozin was co-founder of Hello Health, an integrated telemedicine healthtech company, and founder and Chief Medical Officer of SKMD, a multidisciplinary network of clinics.

Sean Khozin MD, Impact Advisor at Owkin, said:

The possibilities offered by AI in the field of biomedicine are nothing short of extraordinary, and companies like Owkin are leading the charge in this transformative revolution. 

Owkin’s pioneering approach to AI built upon a foundation of privacy preservation and responsible data sharing ensures secure and ethical handling of patient information. By combining this innovative data infrastructure with its unrivaled expertise in AI, Owkin is pushing the boundaries of precision drug discovery and development, setting a new standard in the industry.

With its forward-thinking approach, Owkin is poised to have a significant impact on the lives of millions and bring about a brighter future for precision medicine.

Thomas Clozel MD, Co-founder and CEO at Owkin, said:

Owkin is integrating human and artificial intelligence to discover and develop new drugs and diagnostics. Dr. Khozin’s unrivaled experience at the top of healthcare, pharma and regulation will help Owkin’s first-in-class diagnostics and industry-leading drug discovery and development efforts to reach more doctors, researchers and patients.

We are delighted to be working with him and that Owkin continues to attract the best minds from across the medical world.

About Owkin

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner.

We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.

Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).